Investing

Gilead Reports Relapses on Hepatitis C Drug (GILD)

Shortly after Gilead Sciences Inc. (NASDAQ: GILD) announced its $11 billion acquisition of Pharmasett, the company also reported some very promising results on a hepatitis C drug that came in the acquisition. Today, those results were trimmed back and Gilead’s…

By Paul Ausick
Published February 17, 2012, 7:17am ET · 1 min read

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Shortly after Gilead Sciences Inc. (NASDAQ: GILD) announced its $11 billion acquisition of Pharmasett, the company also reported some very promising results on a hepatitis C drug that came in the acquisition. Today, those results were trimmed back and Gilead’s shares are taking a beating in the pre-market.

In the earlier report, the drug, called GS-7977, when used in combination with ribavirin eliminated all symptoms of a certain type of hepatitis C in just four weeks. Today’s report indicates that in a certain type of the disease, test results showed that six of eight patients “experienced viral relapse.”

Gilead shares are down nearly -19% at $44.50 in the pre-market.

Gilead’s announcement is available here.

Contact [email protected] for any questions or corrections.

1INVESTMENTS ARE NOT FDIC INSURED • ARE NOT BANK GUARANTEED • MAY LOSE VALUE

Brokerage and Active investing products offered through SoFi Securities LLC, member FINRA(www.finra.org)/SIPC(www.sipc.org).2The probability of a member receiving $3,000 is 0.028%. If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Members must fund their account with a minimum of $50.00 to qualify. The probability percentage is subject to decrease. Members are only eligible for the Stock Award promotion upon opening their first brokerage account; subsequent cash brokerage accounts are ineligible for the promo, including for members with multiple accounts.

3Other fees, such as exchange fees, may apply. Please view our fee disclosure to view a full listing of fees.

4There are limitations with fractional shares to consider before investing. During market hours fractional share orders are transmitted immediately in the order received. There may be system delays from receipt of your order until execution and market conditions may adversely impact execution prices. Outside of market hours orders are received on a not held basis and will be aggregated for each security then executed in the morning trade window of the next business day at market open. Share will be delivered at an average price received for executing the securities through a single batched order. Fractional shares may not be transferred to another firm. Fractional shares will be sold when a transfer or closure request is initiated. Please consider that selling securities is a taxable event.
Paul Ausick

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

All articles →